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ABSTRACT
To characterize the organization of mtDNA–protein
complexes (known as nucleoids) in vivo, we have
probed the mtDNA surface exposure using
site-specific DNA methyltransferases targeted to
the mitochondria. We have observed that DNA
methyltransferases have different accessibility to
different sites on the mtDNA based on the levels of
protein occupancy. We focused our studies on
selected regions of mtDNA that are believed to be
major regulatory regions involved in transcription
and replication. The transcription termination
region (TERM) within the tRNA
Leu(UUR) gene was
consistently and strongly protected from methyla-
tion, suggesting frequent and high affinity binding
of mitochondrial transcription termination factor 1
(mTERF1) to the site. Protection from methylation
was also observed in other regions of the mtDNA,
including the light and heavy strand promoters (LSP,
HSP) and the origin of replication of the light strand
(OL). Manipulations aiming at increasing or decreas-
ing the levels of the mitochondrial transcription
factor A (TFAM) led to decreased in vivo methyla-
tion, whereas manipulations that stimulated
mtDNA replication led to increased methylation.
We also analyzed the effect of ATAD3 and oxidative
stress in mtDNA exposure. Our data provide a
map of human mtDNA accessibility and demon-
strate that nucleoids are dynamically associated
with proteins.
INTRODUCTION
The human mitochondrial genome is organized in
DNA–protein complexes known as nucleoids. A variety
of processes including replication, transcription and
repair occur in the context of these structures (1,2). Each
human nucleoid is believed to contain two to eight
mtDNA molecules (3). Nucleoids are actively distributed
during mitochondrial fusion and ﬁssion ensuring proper
segregation of mitochondrial genomes (4). Biochemical
isolation procedures have identiﬁed several nucleoid
components such as DNA polymerase gamma catalytic
subunit (POLGA), a putative mtDNA helicase
(Twinkle), mitochondrial transcription factor A (TFAM)
and mitochondrial single stranded binding protein
(mtSSB) (5). While some components of the mitochon-
drial nucleoids have been identiﬁed, nucleoid structural
organization and dynamics remain poorly understood
in mammalian cells. It has been speculated that during
mtDNA replication and under certain physiological
conditions nucleoid composition and structure varies.
The high mobility group (HMG) family protein,
TFAM, has been reported as the most abundant
nucleoid component (6). Members of HMG proteins are
able to bind, bend and unwind DNA (7). TFAM is
involved in mtDNA maintenance, transcription, replica-
tion, and is thought to play a major role in mtDNA
packaging and compaction similar to histone proteins
and bacterial HU protein (2,6). Ablation of TFAM in
mice results in embryonic lethality due to severe mtDNA
depletion (8). Over-expression of TFAM is suﬃcient to
increase mtDNA transcription; however, high levels of
TFAM are not necessarily correlated with increased
mtDNA copy number (9,10). TFAM binding to DNA
has a low degree of speciﬁcity; however, it has been
shown to bind with higher aﬃnity to the light- and
heavy-strand promoters, LSP and HSP (11). The ratio
of TFAM/mtDNA is currently a controversial issue. In
HeLa cells, 900–1700 molecules of TFAM were reported
to be associated with one molecule of mtDNA (2). It has
been estimated that TFAM occupies  25bp, therefore 900
molecules of TFAM would be enough to coat the entire
mitochondrial genome (11–13). Accordingly, atomic
force microscopy experiments have shown that TFAM
alone has the capacity to fully compact mtDNA (14).
However, it is still not known whether mtDNA is fully
saturated with TFAM in vivo. In contrast, more
recently, TFAM was reported to be present at lower quan-
tities in HeLa cells ranging from 35 to 50 molecules per
mtDNA (15,16). This estimate would restrict the number
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That relatively low TFAM:mtDNA ratio was demon-
strated to be enough to stimulate mtDNA transcription,
whereas much higher concentrations of TFAM had an
inhibitory eﬀect on transcription (15).
In the present study, we adopted an approach
previously used for nuclear DNA to identify potential
mtDNA–protein interactions in living cells. The use of
prokaryotic DNA methyltransferases has been shown to
be a powerful strategy in mapping in vivo DNA binding
sites of chromatin proteins (17–19). DNA regions coated
by proteins are less accessible to methyltransferases,
whereas ‘naked’ DNA is easily methylated. Similar to
chromatin structures, mitochondrial nucleoids are also
dynamic and regulated by remodeling protein complexes.
Therefore, in order to map methyltransferase accessibility
to mtDNA, we targeted two bacterial DNA methyl-
transferases to mitochondria, M.ApaI which recognizes
low frequency GGGCCC sites and M.CviPI which
recognizes higher frequency GpC dinucleotide sites.
Using this approach, we identiﬁed changes in methyl-
transferases accessibility to the mtDNA in response to
diﬀerent cell treatments that modify the nucleoid
environment.
MATERIALS AND METHODS
Construction of DNA methyltransferases genes targeted
to the mitochondria
The gene encoding for ApaI methyltransferase (M.ApaI)
was PCR ampliﬁed from the Acetobacter pasteurianus
genome. pSH1052 plasmid containing an insert encoding
for M.CvipI was kindly provided by Dr Michael
P. Kladder, University of Florida. A mitochondrial
target sequence from the cytochrome oxidase subunit
VIII was added in frame to the 50-end of the genes, and
an HA tag was included at the 30-end. The ﬁnal constructs
were cloned in a Mifepristone (RU486) inducible vector
derived from the Gene Switch System (Invitrogen) to
tightly control the expression of the genes. The gene
encoding for TFAM was PCR ampliﬁed from a human
cDNA library and cloned into a vector driven by a CMV
promoter containing a pIRES GFP. The Mito-M.CvipI-
HA gene was also cloned in a pIRES-GFP lentivirus
vector under control a CMV promoter. Lentivirus was
prepared by the Viral Vector core Facility Miami Project
to Cure Paralysis, University of Miami.
Cell cultures and DNA transfections
Human osteosarcoma 143B, human embryonal kidney
(HEK) 293T and HeLa cells were cultured in Dulbecco’s
medium supplemented with 1mM sodium pyruvate,
50mg/ml uridine and 10% fetal bovine serum. For
plasmid transfections, cells were plated at  70% con-
ﬂuence in 6-well tissue culture plates and plasmids were
transfected using Fugene reagent (Roche) as described
by the manufacturer. After 48h, transfected cells with
mito-M.CviPI were selected using 100mg/ml hygromycin
B (Invitrogen). Stable clones were isolated after 2wks
of selection. For Lentiviral infections, 1 10
5cells were
seeded in 6-well plates and transduced with 6 10
6pg of
viral particles.
siRNAs for TFAM, mTERF and ATAD3 knockdown
TFAM, mTERF and ATAD3 siRNAs were synthesized
using the Silencer siRNA construction kit (Ambion). To
knockdown TFAM, two siRNAs against exon 4 were
used: AAGTTGTCCAAAGAAACCTGT and AAGAT
GCTTATAGGGCGGAGT corresponding to mRNA nt
273–293 and nt 431–451, respectively (10). mTERF1 was
target using AAGCGGGUGAAAGCUAACAUU cor-
responding to mRNA nt 585–605 (20). To knockdown
ATAD3 expression, cells were transfected with siRNA
against 50-UCAAUGAGGAGAAUUUACGGAAGCA
AG-30 (21). Cells were transfected with 20nm of siRNA
using Lipofectamine RNAiMAX (Invitrogen).
Immunocytochemistry
Cells were gown on coverslips and induced with 10nM
RU486 (Invitrogen). After 24h, cells were incubated
with 200nM CMX-ROS Mitotracker
TM (Invitrogen) for
20min. Cells were washed with PBS and ﬁxed with 4%
paraformaldehyde and permeabilized with cold methanol
for 5min and stained with rat anti-HA antibody (Roche)
and anti-rat IgG Alexa-ﬂuor 488 secondary antibody
(Invitrogen). Images were obtained using a confocal
Axiovert 100M microscope with a LSM510 scanning
module (Carl Zeiss).
Southern blotting
Approximately 0.5mg of genomic DNA was subjected to
ApaI digestion for 4h. Samples were resolved in a 0.8%
agarose gel and transferred to a Zeta-Probe GT
membrane (Bio-Rad, Hercules, CA). Membranes were
hybridized with [a-
32P] dCTP-labeled random primed
probes generated against a 16kb mtDNA template.
Images were recorded using a Cyclone Storage Phosphor
System and analyzed using the associated Optiquant
software (Perkin Elmer).
Western blotting
Thirty micrograms of proteins from cell homogenates
were subjected to electrophoresis in a 4–20% Tris–HCl
polyacrylamide gel (Bio-Rad) and transferred to a
PVDF membrane (Bio-Rad). Membranes were probed
with anti-TFAM and anti-b-tubulin antibodies (Sigma,
Saint Louis, MO). HRP-conjugated secondary antibodies
(Sigma) were used and reactions were developed using
Super Signal West Pico Chemiluminescent Substrate
(Pierce, Rockford, IL).
Real-time PCR
mRNA from cells transfected with TFAM and ATAD3
siRNAs were harvested using an RNeasy kit (Qiagen).
cDNAs were synthesized using Superscript reverse trans-
criptase (Invitrogen). Real-time PCR using CYBR green
(Qiagen) was performed in order to detect TFAM and
ATAD3 mRNA expression levels. Gene expression levels
were normalized against beta actin values. Primer design
6702 Nucleic Acids Research, 2009,Vol.37, No. 20was aided by Biosearch Technologies at http://www.
biosearchtech.com/products/probe_design.asp.
Bisulﬁte genomic PCR
Genomic DNA was extracted and bisulﬁte treated with
the EpiTect Bisulﬁte Kit (Qiagen). Bisulﬁte-treated DNA
was PCR ampliﬁed with various primers ﬂanking mtDNA
regions of interest. Cycling conditions were: 3min at 94 C,
45 cycles of 30s at 94 C, 30s at 50 C, 30s at 72 C
followed by 4min at 72 C. PCR products were puriﬁed
by GenElute PCR Clean-Up Kit (Sigma-Aldrich) and
sequenced by a commercial facility (Genewiz).
Methylation quantiﬁcation
Mutation Surveyor software (Softgenetics) was used to
analyze the ab1 sequencing ﬁles from bisulﬁte converted
samples. Mutation surveyor detected methylation as point
mutation (GT>GC) by comparing the sequencing trace
data of methylated samples to a reference (unmethylated)
sample. Trace intensities were obtained using the Output
Trace Data function and exported to an Excel ﬁle. The
trace data from methylated samples were normalized by
the trace data from unmethylated control samples. The
intensity ratio of the Thymine (T) peaks corresponding
to the GpC sites of methylated and control samples was
calculated. The average of the intensity ratio of 8 T peaks
surrounding the GpC site was also determined. The
thymine peak corresponding to a methylated GpC site
subtracted and divided by the average of the thymine
peak values is equivalent to the level of methylation at a
particular site. A selected mtDNA segment in the D-loop
region was ampliﬁed, treated and analyzed independently
in triplicate. This analysis showed essentially identical
levels of protection (not shown).
RESULTS
Expression of DNA methyltransferases targeted to
mitochondria
We constructed two genes encoding bacterial methyltrans-
ferases, M.ApaI and M.CviPI, to have their products
targeted to the mitochondria. The M.ApaI recognizes
speciﬁcally the GGGCCC sequence and it was selected
because it can probe the occupancy of mTERF1 in the
TERM region of the tRNA
Leu(UUR) gene in cells that
harbor the MELAS (Mitochondrial Encephalomyopathy
Lactic Acidosis and Stroke-like episodes) A3243G
mutation. The M.CviPI methyltransferases GpC sites,
which occur at a high frequency in the mtDNA (710
sites), was used for a more detailed in vivo mapping of
methyltransferases accessibility to the mitochondrial
genome. For mitochondrial targeting and immuno-
detection, the COX8 mitochondrial targeting sequence
(MTS) was added to the N-terminus of each gene and
an HA immuno-tag was added to the C-terminus
(Figure 1). In order to better control the expression
levels of the mito-methyltransferases, the ﬁnal constructs
were cloned in a RU486 (mifepristone) inducible vector
derived from the Gene Switch system (Invitrogen).
The mito-M.ApaI-HA construct was stably transfected
into 143B cybrids homoplasmic for the MELAS
mutation and mito-M.CviPI-HA was stably transfected
into HEK293T cells. Confocal microscopy conﬁrmed the
expression of both methyltransferases in the mitochondria
of both cell types after 24h induction (Figure 1).
mTERF1 binding site is strongly protected against
methylation
Southern blot analysis with a methylation-sensitive
restriction enzyme was performed to evaluate the ability
of cells stably expressing mito-M.ApaI-HA to methylate
mtDNA. In this assay, total genomic DNA was digested
with the cognate M.ApaI restriction endonuclease, ApaI,
which recognizes the same sites as M.ApaI. Methylation
of cytosine on both DNA strands by M.ApaI inhibits
cleavage by ApaI restriction endonuclease. Genomic
DNA extracted from wild-type, MELAS cybrids and
two mito-M.CviPI-HA clones induced with mifepristone
for 24h were digested with ApaI. As an experimental
control, we performed an in vitro methylation assay by
treating genomic DNA with a commercial GGCC
methyltransferease (M.HaeIII) for diﬀerent time points
followed by digestion with ApaI (Figure 2b, lanes 5–10).
In both cases probes generated against the entire mtDNA
were used to visualize mtDNA fragments.
The Southern blot methylation assay revealed that
mtDNA from wild-type and mutant control cells not
transfected with mito-M.ApaI-HA were completely
digested by ApaI restriction endonuclease. In contrast,
mito-M.ApaI-HA cells showed partial digestion, reﬂecting
partial methylation of ApaI recognition sites (Figure 2).
The partial digestion is seen as extra bands not present in
the wild-type and mutant control samples. The same
pattern of partial digestion was also seen in the ‘short-
incubation’ in vitro methylation assay samples conﬁrming
the partial methylation in vivo. Interestingly, the ﬁve
common ApaI sites that are present in both wild-type
and mutant mtDNA were partially methylated in the
mito-M.ApaI-HA expressing cells, but the unique ApaI
site within the mTERF1 binding site created by the
MELAS mutation was completely digested indicating it
was not methylated. This ApaI site generates two new
bands (1.7 and 1.2kbp) that are equivalent to cleavage
of the 2.9kbp in the wild-type mtDNA. Undigested
2.9kbp was present in the in vitro methylation samples
suggesting that M.ApaI was not able to access the ApaI
mtDNA site within the mTERF binding site in living cells.
As it was observed before, in the nuclear genome, we
believed that protection from methylation is due to
protein–DNA contacts that inhibit the access of DNA
methyltransferases. The mitochondrial transcription
termination factor 1 (mTERF1) is the only protein
known to bind to the mtDNA region that includes this
particular ApaI site.
Identiﬁcation of mtDNA protected sites with a GpC
methyltransferase targeted to the mitochondria
Because the M.CviPI methyltransferase recognizes all 710
GpC sites in mtDNA, we used this construct for a more
Nucleic Acids Research, 2009,Vol.37, No. 20 6703detailed mapping of selected regions. Because of the larger
number of sites, we performed bisulﬁte genomic PCR
followed by quantitative electropherogram analysis
rather than Southern blotting in order to determine the
methylation status of mtDNA in HEK293T cells
expressing mito-M.CviPI-HA. This technique is based
on the deamination of cytosine, but not 5-methyl-
cytosine, to uracil by sodium bisulﬁte (22). Cells
transfected with mito-M.CviPI-HA were induced with
mifepristone for 24h followed by genomic DNA extrac-
tion and bisulﬁte genomic PCR. We investigated three
major regulatory regions of the mtDNA: the D-loop or
major non-coding region (NCR), the binding site for
mTERF1 (TERM) and the origin of the L-strand
replication (OL).
The height of the electropherogram peaks does not
reﬂect the percentage of the speciﬁc base precisely. To
more accurately quantify the methylation levels at each
Figure 2. Southern blot methylation assay showing partial methylation of cells expressing ApaI methyltransferase. Panel A shows the expected band
sizes after ApaI restriction endonuclease digestion of the human mtDNA harboring the MELAS A3243G mutation. The arrow shows the mutated
3243 site (an ApaI site), within the binding site of mTERF1. If this site is not digested, the 1.2 and 1.7kb bands merge into a 2.9kb band. Panel B
shows the Southern blot of DNA from the mutant cells after expression of M.ApaI and controls. The absence of the 2.9kb band in the M.ApaI
expressing clones indicates methylation protection at the 3243 G position. The arrow in panel B indicates wild-type band which is absent from
samples that have the MELAS mutation. Methylation of naked DNA (in vitro) does not protect the 3243G.
Figure 1. Construction and expression of methyltransferases targeted to the mitochondria. A DNA fragment coding for a mitochondria targeting
sequence (MTS) derived from the COX VIII gene was added to the 50-end of the DNA methyltransferase genes and a HA tag was added to the
30-end of the genes. The upper panel shows co-localization of ApaI methyltransferase and mitotracker in human osteosarcoma cells transfected with
mito-M.ApaI-HA. The lower panel shows a similar experiment performed in HEK293T cells transfected with mito-M.CviPI-HA.
6704 Nucleic Acids Research, 2009,Vol.37, No. 20GpC site from sequencing electropherograms, we used
a novel mutation quantiﬁer function developed for the
Mutation Surveyor software (Softgenetics, http://www
.softgenetics.com/mutationSurveyor.html). Mutation
surveyor software detects GpC methylation in ABI trace
ﬁles from bisulﬁte treated DNA as a GT—>GC mutation
compared to a reference (unmethylated) trace ﬁle. DNA
methylation quantiﬁcation is determined by quantifying
the drop of the T peak intensity of the methylated
sample compared to the unmethylated sample taking
into account context dependent variations in T peak
heights. We have also obtained similar results by using a
recently described method known as Mquant (23).
Mquant uses a similar algorithm method based on the
peak area determination from sequencing electrophero-
grams and has been shown to give results consistent
with the well-established combined bisulﬁte restriction
assay (COBRA) (24). Using the Mutation Surveyor
software, we observed diﬀerential accessibility to the
M.CviPI methyltransferase (Figures 3–5). The most pro-
tected GpC sites identiﬁed were located upstream the
mt3L, consensus binding site for nuclear protein factors
(25), region (GpC site 16536), in the LSP promoter (GpC
site 418), in the HSP and nearby regions (GpC sites 418,
602, 698 and 702), The TERM (GpC sites 3240, 3245 and
3256) and in the OL region (GpC sites 5624, 5755, 5764
and 5798). Among these sites, the TERM region was
completely protected from methylation (Figure 5 and
Supplementary Figure S1) as observed with the ApaI
methyltransferase. We observed low levels of protection
from methylation in the LSP and HSP regions cor-
responding to the canonical TFAM binding sites
(Figure 4). This result suggests that proteins occasionally
coat the promoter region, but to a lesser frequency or
aﬃnity when compared to the mTERF1 binding to the
TERM site. It is possible that D-loop accessibility is
modulated during transcription and replication, when
factors are required to access the OH, LSP or HSP. The
protection at the non-coding region of the OL also
suggests high aﬃnity binding of factors to that region.
To conﬁrm that the lack of methylation seen in the
mTERF1 binding site in MELAS cells was due to
mTERF1 occupancy (Figure 3B), we silenced the expres-
sion of mTERF1 using RNA interference. mTERF1
speciﬁc siRNA was transfected into HEK293T stably
transfected with mito-M.CvipI-HA gene. Real-time PCR
revealed a decrease in mTERF1 mRNA of 75% compared
to control at 72h post siRNA transfection (Figure 3A).
As expected, down-regulation of mTERF1 resulted in
increased mtDNA methylation in the TERM region
(Figure 3C). In contrast to the increased methylation
following down-regulation of mTERF1, down-regulation
of TFAM did not aﬀect methylation in the TERM region
(Figure 3D).
Comparison of the mtDNA methylation pattern
in diﬀerent cells lines
Because there is a discrepancy regarding the ratio of
TFAM/mtDNA in diﬀerent cell types, it is possible that
TFAM may occupy all available mtDNA sites in some
cells, making it more compact and less accessible to the
methyltransferase. To investigate whether methyltrans-
ferase accessibility to mtDNA might be cell-type speciﬁc,
we transduced 143B and HeLa cells with a lentivirus
vector encoding for the Mito-M.CviPI-HA gene,
allowing a direct comparison with the results from our
inducible mito-M.CviPI-HA HEK293T model. Both
transduced and induced cells shared some methylation
protectionsites,indicating aconservedstructuralorganiza-
tion and protein–DNA interactions at particular sites
(Figures 4 and 5). Similar pattern of protection was
observed at the mt3L, OH, LSP, HSP1, HSP2 and
TERM regions. However, 143B and HeLa showed lower
levels of methylation in the 12S rRNA (e.g. nts 761–851)
and D-loop upstream of HVS1 (e.g. 16190–16340). The
TFAM binding site at GpC site 418 (LSP) showed the
highest degree of protection in HeLa cells when
compared to 143B and HEK293T. We also observed
Figure 3. TERM site in the tRNA leucine gene is strongly protected
from methylation. (A) qRT-PCR showing the relative decrease in the
levels of mTERF1 mRNA after 72h of siRNA treatment. (B) Diagram
shows mTERF1 binding site in the mtDNA TERM region, within the
tRNA
Leu(UUR) (L) gene. (C) Comparison of mtDNA methylation in
control and mTERF1 siRNA transfected cells. The mTERF1 siRNA-
treated sample showed an increase in methylation at the GpC sites
within positions 3240–3256, which correspond to the mTERF1
binding region. (D) mtDNA methylation when TFAM is silenced
does not increase methylation in the TERM region.
Nucleic Acids Research, 2009,Vol.37, No. 20 6705Figure 4. In vivo mtDNA methylation in the NCR (D-loop region) in diﬀerent cell lines. Following in vivo methylation by M.CviPI-HA, either by
miﬁprestone induction (B) or by transduction with a lentiviral vector (C and D), total DNA was puriﬁed and bisulﬁte treated. Sequencing
electropherograms from treated DNA were analyzed and compared to a non-methylated reference sequence. DNA methylation was quantiﬁed by
the percentage drop of Ts (converted Cs) relative to its neighboring peaks (see methods). (A) Diagram showing a map of the major non-coding
region (NCR) of the mtDNA indicating the position of conserved sequence boxes (CSBs), promoter regions (LSP and HSP) and other conserved
cis-elements. It also shows high aﬃnity TFAM binding sites. (B–D) mtDNA methylation levels in HEK293T (B), 143B (C) and HeLa (D) cells.
6706 Nucleic Acids Research, 2009,Vol.37, No. 20strong protection at positions 330 (CSB2) and 514
(upstream of HSP1) in HeLa cells. Conversely, all other
sites in the promoter, OH region and vicinity showed a
high degree of methylation in HeLa cells. Because we
observed a more exposed promoter/OH region and less
exposed TFAM binding sites immediately upstream of
the promoters, it is possible that HeLa mtDNA has
higher rates of transcription when compared to mtDNA
from the other cells. VDAC and cytochrome c oxidase
subunit II (COXII) levels were comparable in all three
cell lines, whereas TFAM and mtDNA levels were lower
in HeLa than in 143B and HEK293T cells (Supplementary
Figure S3). This suggests that HeLa cells have a higher
relative proportion of mtDNA undergoing transcription
at any given time and therefore, more frequent binding of
TFAM to the promoter region.
The mtDNA nucleoids have a less compact state during
mtDNA replication after EtBr treatment
We next used mito-M.CviPI-HA as a tool to analyze
mtDNA nucleoid remodeling during mtDNA replication.
It is not known whether the mammalian mtDNA
undergoes any form of remodeling; however, it has been
Figure 5. In vivo mtDNA methylation in the TERM and OL regions of the mtDNA in diﬀerent cell lines. (A) Map of the regions of the mtDNA
comprising the TERM site and OL. (B–D) mtDNA methylation quantiﬁcation in HEK293T (B), 143B (C) and HeLa (D) cells was determined as in
legend to Figure 4.
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metabolic cues. Yeast mitochondrial nucleoids have a
more open structure under aerobic growth conditions
and a more compact structure under glucose repression
(26). Mammalian mtDNA nucleoids are also dynamic
structures and likely subjected to remodeling. To test
this hypothesis, we analyzed mito-M.CviPI-HA accessi-
bility to mtDNA undergoing active replication following
transient mtDNA depletion. mito-M.CviPI-HA cells were
treated with 50ng/ml EtBr for 10 days, after which the
drug was removed. Southern blots conﬁrmed that the
mtDNA: nDNA ratios changed in a predicted manner
(Figure 6A). We determined the methylation pattern of
samples treated with EtBr for 10 days and collected 48h
after EtBr treatment was removed and mtDNA levels were
recovering (48h EtBr/Rec). With exception of the OL
region (Figure 6D), an increase in methylation levels was
observed in the 48hr EtBr/Rec sample (Figure 6B–C).
These results suggest that the mtDNA nucleoids form a
more open structure during active mtDNA replication.
mtDNA becomes less accessible when TFAM levels are
either up- or down-regulated
To test whether alterations in TFAM levels would aﬀect
the nucleoid structure, we analyzed mtDNA methylation
when TFAM was overexpressed and when its levels were
reduced. In order to overexpress TFAM, HEK293T cells
expressing an inducible mito-m.M.CviPI-HA were trans-
iently transfected with a pIRES-GFP vector encoding
TFAM. Transfected cells were induced with mifepristone
for 24h for methyltransferase expression and GFP
positive cells were sorted by ﬂow-cytometry. Western
blotting of GFP positive cells conﬁrmed TFAM expres-
sion was strongly up-regulated 72h after transfection
(Figure 7A). Most of the GpC sites showed a slight
decrease in methylation when compared to controls
(Figure 8, upper half of panels). However, the decrease
in methylation was more prominent in the mtDNA
promoter region, where TFAM is known to bind with
higher aﬃnity (Figure 8A, upper half). In contrast, we
performed a TFAM knockdown experiment in order to
determine whether TFAM depletion would increase mito-
M.CviPI-HA accessibility (Figure 8, lower half of panels).
Western blotting conﬁrmed that TFAM protein levels
were decreased 48h after siRNA transfection (Figure
7A). We were surprised to observe a decrease in mtDNA
methylation in cells treated with TFAM siRNA after
72h compared to control cells (Figure 8, lower half of
panels). DNA analyses were performed to test whether
TFAM depletion correlated with a decrease in mtDNA
levels. Indeed, mtDNA levels were depleted by  35%
compared to controls (Figure 7B and C). mtDNA was
also decreased when TFAM was overexpressed (Figure
7C and D).
mtDNA methylation is decreased after ATAD3
knockdown
We decided to investigate whether another nucleoid
protein, besides TFAM, could also aﬀect mtDNA struc-
ture and nucleoid organization. It was recently reported
that gene silencing of ATAD3, a mitochondrial membrane
AAA+protein, alters the organization of mtDNA
nucleoids, even though it does not seem to interact
directly with mtDNA (27). Previous work showed that
knockdown of ATAD3 resulted in loss of mtDNA
staining by PicoGreen, suggesting a change in the
mtDNA conformation and topology that excludes
PicoGreen intercalation (21). In order to determine
whether changes in mtDNA topology inﬂuences mito-
M.CviPI-HA accessibility, we knocked down ATAD3
using siRNA. Depletion of ATAD3 levels was conﬁrmed
by real time PCR (Figure 9A). As previously described
(21), a reduction in ATAD3 levels was not accompanied
by mtDNA depletion (Figure 9B). However, we observe
a 1.5 increase in the levels of 7S DNA (Figure 9C).
Decreased mtDNA methylation was observed at most
GpC sites, suggesting that change in mtDNA topology
does reduce mito-M.CviPI-HA accessibility (Figure
9D–F). Since M.CviPI shows considerable preference for
supercoiled plasmid in vitro (Supplementary Figure S2),
we speculate that knockdown of ATAD3 results in
opening of the mtDNA super-coiled structure.
mtDNA nucleoids are transiently more compact during
oxidative stress.
In order to investigate the dynamics of mtDNA nucleoids
remodeling in response to environmental factors, we
exposed mito-M.CviPI-HA cells to oxidative stress
(H2O2). To test the DNA methyltransferase accessibility
to mtDNA in the presence of ROS, Mito-M.CviPI-HA
expressing cells were treated with 200mMH 2O2 for 1h
and subsequently induced for mito-M.CviPI-HA expres-
sion for 1h. We observed an overall decrease in mtDNA
methylation after 1h induction, suggesting a higher
compact state of the mtDNA in the presence of H2O2
(Figure 10). This result suggests that the mtDNA
nucleoid becomes more compact under oxidative stress.
DISCUSSION
By targeting DNA methyltransferases to the mito-
chondria, we have developed a novel tool to identify
protected regions in the mtDNA in living cells. In
contrast, increased methylation frequency observed at
some sites might indicate increased accessibility associated
to DNA bending and looping formation caused by
remodeling factors such as TFAM. When compared to
the average mtDNA methylation level after induction of
mito-M.CvipI, the most protected GpC sites identiﬁed are
located upstream the mt3L region, in the LSP promoter
(mostly in HeLa), in the HSP and nearby regions,
mTERF1 binding site (TERM) and in the OL region.
Our analyses indicate that mtDNA is not methylated in
the cells utilized under standard culture conditions.
Shmookler Reis et al reported that  2–5% mtDNA are
methylated at CCGG regions (28), but there was no
indication of GpC methylation, and these ﬁndings from
the early 80’s, have not been substantiated. Nonetheless,
extreme low percentage of methylation (<5%) would not
be detected by the approach employed.
6708 Nucleic Acids Research, 2009,Vol.37, No. 20Figure 6. mtDNA methylation levels in cells treated with EtBr followed by mtDNA repopulation after EtBr withdraw. (A) Southern blot and
quantiﬁcation of mtDNA relative levels from cells subjected to transient EtBr treatment. Cells were allowed to grow for 24 or 48h without the drug
to allow for active mtDNA repopulation. Southern was probed with an mtDNA and a nuclear 18S rDNA probe. (B–D) Relative changes (to the
untreated control) in methylation of selected mtDNA regions from cell subjected to EtBr+48h recovery treatment.
Nucleic Acids Research, 2009,Vol.37, No. 20 6709The protection of the TERM region was much more
robust than other mtDNA regions, indicating that this
site is persistently occupied. Transcripts initiated at the
HSP promoter (PH1) site give rise to the mitochondrial
rRNAs and are terminated by mTERF1 binding to
TERM. Such transcripts are initiated  50–100 times
more frequently than overlapping transcripts initiated
from HSP promoter PH2 that gives rise to the full-length
heavy-strand transcript (29). mTERF1 has been shown to
bind TERM with high aﬃnity and to be necessary for
mitochondrial rDNA looping required for maintaining
the high levels of rRNA transcription (30). Our results
show that TERM occupancy is very high even under
conditions of TFAM knockdown/overexpression or
recovery from mtDNA depletion, conditions that would
be expected to lead to changes in mtDNA activity and
packaging. It is unclear how transcription proceeds
through this region to generate most of the H-strand-
coded RNAs. It has been reported that mTERF1 binds
OL with moderate aﬃnity (20) and it may be responsible
for the methylation protection observed in the region.
Methylation patterns were conserved in diﬀerent types
of cells and in models based on diﬀerent expression
systems. The mTERF1 binding site showed a similar
degree of protection in all cell lines analyzed; however,
the TFAM binding site to the LSP showed the highest
degree of protection in HeLa cells, possibly because of
more frequent transcription initiation events.
Methylation levels were inﬂuenced by factors known
to initiate changes in the nucleoid environment. Cells
recovering from mtDNA depletion induced by EtBr
treatment, had increased overall methylation levels
indicating a mtDNA less packed with proteins during
active mtDNA replication. Increased mtDNA accessibility
can also be explained by the decreased TFAM: mtDNA
ratio during mtDNA repletion. It has been shown that
TFAM levels, which also get depleted when mtDNA is
not present, recovered to normal levels more slowly than
mtDNA after transient depletion by EtBr treatment (31).
Since TFAM is the most abundant nucleoid protein
involved in mtDNA packaging, a decrease in the
TFAM: mtDNA ratio could result in a less compact
mtDNA. This result supports the idea that the ratio of
TFAM: mtDNA might be a major regulator of mtDNA
activity (i.e. expression/replication), and may vary accord-
ing to cell’s metabolic demands. TFAM has been shown to
be developmentally regulated in Xenopus oocytes (32).
During oogenesis, TFAM levels increase considerably as
the oocyte matures, a stage during which mtDNA activity
is reduced. In yeast the ratio of the TFAM homologue
Abf2 to mtDNA is reduced under respiratory growth
conditions; Conversely, Abf2 levels increase under
glucose repression and amino-acid starvation, making
the mtDNA more compact (24).
In this study, the eﬀects of TFAM levels on mtDNA
accessibility were analyzed and we observed a decrease
in mtDNA methylation when TFAM was either down-
or up-regulated. When TFAM levels were reduced by
siRNA, mtDNA levels were also decreased. However, it
is possible that in this situation other nucleoid com-
ponents may still be present at their own steady-state
levels. This may make the overall structure of nucleoids
less accessible to the methyltransferase. When TFAM is
overexpressed, the mtDNA binding sites in the promoter
region may become saturated with TFAM, suppressing
methyltransferase accessibility. This result supports the
concept that the steady state levels of TFAM is not
enough to fully saturate the mtDNA, otherwise over-
expression of TFAM would not aﬀect methyltransferase
accessibility. It has been demonstrated that excess TFAM
can also lead to mtDNA depletion by causing a shift
towards a slow replication mode (10). We believe that
excess TFAM may result in overcompaction of the
nucleoid and consequently making it diﬃcult for other
replication factors to access the promoter region.
Although moderate increases of TFAM levels can stimu-
late transcription and replication, high concentrations
of TFAM have the opposite inhibitory eﬀect (9). The
decrease in mtDNA methylation was less prominent at
other regions, suggesting that TFAM is not equally
distributed across the mtDNA, not even when it is
present at high concentrations. At high TFAM levels,
the preferential binding speciﬁcity to the promoter
region may be maintained.
Figure 7. Manipulating TFAM levels. (A) Western blot showing
TFAM down-regulation by siRNA and up-regulation by transfection
with a plasmid encoding for TFAM. Tubulin was used as a loading
control. (B and C) Southern blot showing mtDNA depletion in cells
where TFAM is up- or down-regulated. (D) qPCR of mtDNA levels,
expressed as a ratio to the actin gene ampliﬁcation, when TFAM is
overexpressed.
6710 Nucleic Acids Research, 2009,Vol.37, No. 20Figure 8. Changes in mtDNA methylation when TFAM levels are altered. Relative changes in methylation were determined in the following selected
mtDNA regions: NCR (A), TERM (B) and OL (C). Changes were determined when TFAM was either overexpressed (upper part of panels) or down-
regulated (lower part of panels). Methylation of mtDNA was determined as described in legend to Figure 4 and expressed as changes from the
control.
Nucleic Acids Research, 2009,Vol.37, No. 20 6711ATAD3 depletion was also accompanied by a reduction
in mtDNA methylation which might be associated with
changes in mtDNA topology to a more relaxed state.
Increased open circular forms of mtDNA accompanied
by loss of PicoGreen staining was also reported when
prohibitin 1(PHB1), another peripheral nucleoid protein
was knocked down (33). Although the exact function of
ATAD3 remains unknown, it was proposed to be a
peripheral nucleoid protein, which along with PHB1 and
HSP60, surrounds the nucleoid core (25). This suggestion
Figure 9. ATAD3 knockdown resulted in decreased mtDNA methylation. (A) Quantitative RT-PCR of a HEK293T treated with ATAD3 siRNA
showed decreased levels of ATAD3 mRNA. (B) Southern blot of treated cells showed that mtDNA levels in cells transfected with ATAD3 siRNA
were not altered. (C) Southern blot of siRNA for ATAD3 treated cells detected an increase in 7S DNA/mtDNA relative levels. Down-regulation of
TFAM did not aﬀect the ratio of 7S DNA/mtDNA whereas up-regulation of TFAM caused a decrease in 7S DNA/mtDNA relative levels. (D–F)
Quantiﬁcation of relative changes in methylation in cells transfected with ATAD3 siRNA in the following selected regions: NCR (D), TERM (E) and
OL (F).
6712 Nucleic Acids Research, 2009,Vol.37, No. 20was based on the fact that ATAD3 has been found in
nucleoid preparations (5) and it has a high binding
aﬃnity to D-loop structures in vitro (21). However,
others have demonstrated that ATAD3 fails to crosslink
to mtDNA and it cannot bind mtDNA in vivo (25).
Whether ATAD3 interacts with mtDNA directly or not,
it may still have a role in structural remodeling of
mtDNA. More work will be required to test how
peripheral nucleoid proteins play a role in mtDNA
organization and stability.
Finally, we used the in vivo methylation approach to
look for changes in nucleoid structure triggered by
oxidative stress. mtDNA is quite sensitive to reactive
oxygen species (ROS), since it does not have a complex
chromatin organization. TFAM may play an important
role in protecting the mtDNA against oxidative damage
and as well as repairing the mtDNA. It has been
demonstrated that sub-lethal doses of H2O2 cause a
drastic increase in the ratio of TFAM protein per
mtDNA (34). In addition, Yoshida et al. (35) demonstra-
ted that TFAM preferentially binds oxidatively damaged
DNA in vitro. The increased binding aﬃnity of TFAM
to oxidative damaged DNA, may modulate the mtDNA
structure to a more compact state than normal.
Accordingly, we observed an overall decreased mtDNA
methylation when cells were exposed to H2O2 for 1h. A
potential caveat, is that because M.CvipI recognizes GpC
sites, it is possible that methylation could be inhibited by
the presence of 8-hydroxy-20-deoxyguanosine (8-oxodG).
However, it has been demonstrated that 8-oxoG content
in circular mtDNA is relatively low after oxidative stress
(36,37). Because 8-oxodG can be removed from the
mtDNA by a base excision repair process involving
8-oxoguanine DNA glycosylase (OGG1) (38), the recruit-
ment of repair enzymes may reduce the accessibility of
mtDNA to M.CviPI. It is also possible that nucleoids
remodel into a more compact state during oxidative
stress to provide a more insulated environment for
mtDNA. As mentioned above, the changes we observed
in mtDNA methylation during oxidative stress may be
regulated by interaction between TFAM and mtDNA.
Other nucleoid factors may also play a role in protecting
mtDNA against ROS. Recently it has been shown that
SOD2 (manganese superoxide dismutase) is an integral
Figure 10. mtDNA methylation levels are decreased when cells are exposed to H2O2.( A) Quantiﬁcation of relative changes in methylation in cells
treated with H2O2 in the following selected regions: NCR (A) and OL (B).
Nucleic Acids Research, 2009,Vol.37, No. 20 6713nucleoid protein that could confer mtDNA protection
against ROS (39). In addition, the mismatch repair
enzyme, MYH is recruited to oxidized DNA in order to
excise A/8-oxodG mismatch (24). All these factors could
contribute to a more packed mtDNA that is less accessible
to the methyltransferase. More detailed analysis of
mtDNA interactions with protein factors will help eluci-
date the functional dynamics of mitochondrial nucleoid
structures.
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